Exhibit 99.1
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales which enables the company toCommercializebrands that fill unmet patient and physician needs;Developnew products through life cycle management; andIn-Licensephase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OBGYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcements: Bradley Pharmaceuticalswill present at the Robbins Emerging Opportunities Investment Conference, to be held at The University Club in New York, NY, May 24, 2007.
Bradley Pharmaceuticalswill present at the Banc of America Securities Health Care Conference 2007, to be held at The Four Seasons Hotel in Las Vegas, Nevada, May 30 - June 1, 2007.
Bradley Pharmaceuticalswill present at the FTN Midwest Securities Health Care Conference 2007, to be held at the Four Seasons Hotel in New York, NY, June 5, 2007.
| For Immediate Release | Contact: | Cecelia C. Heer
Investor Relations
Bradley Pharmaceuticals, Inc.
973-882-1505, ext. 252 |
BRADLEY PHARMACEUTICALS
2007 FIRST QUARTER RESULTS
Fairfield, NJ – May 10, 2007 - BRADLEY PHARMACEUTICALS, INC. (NYSE: BDY) announced today that it has filed with the Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.
First Quarter 2007 Accomplishments
| | - | | Net sales increased 9% compared to same period last year |
| | - | | Net income increased $2.3 million compared to same period last year |
| | - | | Generated approximately $11.5 million of cash flow from operating activities |
| | - | | Estimated product in the distribution channel decreased $3.2 million from December 31, 2006 to March 31, 2007 |
| | - | | Increased cash and cash equivalents, short-term investments and restricted cash position by $6.2 million |
| | - | | Principal payments of $3.7 million on our credit facility |
| | - | | Elestrin™ received new patent extending patent life to 2022 |
Bradley reported that net sales for the quarter ended March 31, 2007 were approximately $37.8 million, an increase of $3.0 million, or 9%, over net sales for the quarter ended March 31, 2006. Net income for the 2007 quarter amounted to $2.5 million, or $0.15 per share on a fully diluted basis, based upon approximately 16.8 million shares outstanding, compared to $0.01 per share on a fully diluted basis, based upon approximately 16.5 million shares outstanding for the same period last year. Net income for the quarter ended March 31, 2006 included an initial licensing fee, which was included in research and development expenses, of $5.0 million ($2.9 million after tax or $0.18 per share) for VEREGEN™.
Doak Dermatologics, led by its core branded products of ADOXA®, KERALAC®/ KEROL™, SOLARAZE®, ZODERM®, LIDAMANTLE®, and ROSULA®, accounted for 75% of our net sales for quarter ended March 31, 2007, while Kenwood Therapeutics, and its core branded products of PAMINE®, ANAMANTLE HC® and FLORA-Q®, accounted for the remaining 25% of our net sales for the quarter ended March 31, 2007. We have not yet recognized revenues for A. Aarons, our generic subsidiary that began operations in the third quarter of 2006. During 2006 and in the first quarter of 2007, A. Aarons shipped approximately $0.3 million and $2.0 million, respectively, of products at each product’s respective gross selling price. The Company has recorded in accrued expenses deferred revenue of $0.6 million from these sales at March 31, 2007, which represent the payments received from customers through that date.
The increase in our net sales for the quarter ended March 31, 2007 was primarily led by the actinic keratosis product SOLARAZE® (diclofenac sodium-3%) and the gastrointestinal and respiratory products, but Bradley’s sales continue to be affected by generic and therapeutically equivalent products competing on price. The following table sets forth certain net sales data for the quarters ended March 31, 2007 and March 31, 2006 by therapeutic category within Doak Dermatologics and Kenwood Therapeutics:
| Therapeutic Category by Company | March 31,
2007
| March 31,
2006
| Increase/
(Decrease)
| %
Change
|
|---|
| Doak Dermatologics | | | | | | | | | |
| Dermatology & Podiatry | |
| Keratolytic | | $ 4,868,000 | | $ 5,935,000 | | $(1,067,000 | ) | (18 | )% |
| Acne/Rosacea | | 14,427,000 | | 15,396,000 | | (969,000 | ) | (6 | )% |
| Actinic Keratoses | | 5,334,000 | | 4,107,000 | | 1,227,000 | | 30 | % |
| Anesthetics | | 1,638,000 | | 1,413,000 | | 225,000 | | 16 | % |
| Scalp | | 283,000 | | 392,000 | | (109,000 | ) | (28 | )% |
| Cosmeceuticals | | 1,424,000 | | 1,138,000 | | 286,000 | | 25 | % |
| Authorized Generic | | 269,000 | | 966,000 | | (697,000 | ) | (72 | )% |
| Other | | 95,000 | | 56,000 | | 39,000 | | 70 | % |
|
| |
| |
| |
| |
| Total Doak Dermatologics | | 28,338,000 | | 29,403,000 | | (1,065,000 | ) | (4 | )% |
| | |
| Kenwood Therapeutics | |
| Gastrointestinal | | 6,553,000 | | 4,712,000 | | 1,841,000 | | 39 | % |
| Respiratory | | 2,513,000 | | 290,000 | | 2,223,000 | | 767 | % |
| Nutritional | | 344,000 | | 300,000 | | 44,000 | | 15 | % |
| Other | | 55,000 | | 48,000 | | 7,000 | | 15 | % |
|
| |
| |
| |
| |
| Total Kenwood Therapeutics | | 9,465,000 | | 5,350,000 | | 4,115,000 | | 77 | % |
| | | | | | | | | | |
| Total Bradley Pharmaceuticals, Inc. | | $37,803,000 | | $34,753,000 | | $ 3,050,000 | | 9 | % |
|
| |
| |
| |
| |
During the quarter ended March 31, 2007, we increased cost of sales by $0.9 million due to an increase in inventory reserve as a result of our initiatives to reduce potential future returns. During April 2007, we initiated a returns and inventory optimization plan, which includes shipping products with increased shelf-life to our customers. Primarily due to the increase in inventory reserves, the gross profit percentage for the three months ended March 31, 2007 decreased to approximately 82% from 86% in the corresponding period of 2006.
We expect to launch ELESTRIN™ at the end of the second quarter of 2007 and VEREGEN™ at the end of 2007. ELESTRIN™ will be promoted to physicians by our Kenwood Therapeutics sales force. VEREGEN™ will be promoted to physicians by both our Doak Dermatologics and Kenwood Therapeutics sales forces. In connection with the launch of these products, we anticipate hiring approximately 20 additional Kenwood Therapeutics sales representatives during 2007 and incurring a corresponding amount of additional sales, marketing and related expenses.
Other Information:
For more detailed information, please see Bradley’s filings, including its recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, by visiting www.bradpharm.com and clicking on the Investor Relations link, then on SEC Filings.
Bradley Pharmaceuticals Inc. invites you to participate in the Company’s First Quarter 2007 Earnings Conference Call on Monday, May 14, 2007 at 9 AM ET. To participate in the conference call, please dial 1-888-573-3046 approximately 10 minutes prior to the start of the call and enter ID# 8540405.
Playback of the conference call will be available after 1:00 PM ET by calling 1-800-642-1687 and entering reservation ID# 8540405. The call also will be available on our web page for 30 days.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Safe Harbor for Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley’s plans to in-license, develop and launch new and enhanced products
with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley’s products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to: launch VEREGEN™ at the end of 2007 and ELESTRIN™ at the end of the second quarter 2007; predict the safety and efficacy of these products in a commercial setting; estimate sales; maintain adequate inventory levels; implement the returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Important Product Safety Information:
SOLARAZE®
Sun avoidance is indicated during SOLARAZE® Gel therapy. As with other NSAIDs, anaphylactoid reactions may occur in patients without prior exposure to diclofenac. Diclofenac sodium should be given with caution to patients with the aspirin triad. In clinical trials, the most common adverse reactions involved the skin and included contact dermatitis, rash, dry skin and exfoliation. The majority of these reactions were mild to moderate, and resolved upon discontinuation of therapy. SOLARAZE® Gel should not be applied to open skin wounds, infections, or exfoliative dermatitis. Please see full prescribing information at http://www.bradpharm.com.
BRADLEY PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
| Three Months Ended
|
|---|
| March 31,
2007
| March 31,
2006
|
|---|
| Net sales | | $ 37,802,957 | | $ 34,753,358 | |
| Cost of sales (1) | | 6,682,255 | | 5,005,649 | |
|
| |
| |
| | | 31,120,702 | | 29,747,709 | |
|
| |
| |
| Selling, general and administrative expense | | 21,296,255 | | 19,893,498 | |
| Research and development expense | | 680,444 | | 5,262,724 | |
| Depreciation and amortization expense | | 2,927,791 | | 2,550,178 | |
| Interest expense | | 2,266,408 | | 2,114,016 | |
| Interest income | | (554,354 | ) | (427,040 | ) |
|
| |
| |
| | | 26,616,544 | | 29,393,376 | |
|
| |
| |
| Income before income tax expense | | 4,504,158 | | 354,333 | |
| Income tax expense | | 1,979,606 | | 149,000 | |
|
| |
| |
| Net income | | $ 2,524,552 | | $ 205,333 | |
|
| |
| |
| Basic net income per common share | | $ 0.15 | | $ 0.01 | |
|
| |
| |
| Diluted net income per common share | | $ 0.15 | | $ 0.01 | |
|
| |
| |
| Shares used in computing basic net income per | |
| common share | | 16,570,000 | | 16,380,000 | |
|
| |
| |
| Shares used in computing diluted net income per | |
| common share | | 16,780,000 | | 16,500,000 | |
|
| |
| |
| (1) | | Amounts exclude amortization of intangible assets related to acquired product. |
BRADLEY PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| March 31,
2007
(unaudited)
| December 31,
2006
(a)
|
|---|
| Assets | | | | | |
| Current assets: | |
| Cash and cash equivalents | | $ 46,486,635 | | $ 39,608,987 | |
| Short-term investments | | 6,373,772 | | 7,083,678 | |
| Accounts receivable, net of allowances | | 9,853,451 | | 14,489,623 | |
| Inventories, net | | 7,268,571 | | 6,881,218 | |
| Deferred tax assets | | 15,098,121 | | 13,332,666 | |
| Prepaid expenses and other | | 2,406,547 | | 2,100,487 | |
| Prepaid income taxes | | — | | 4,934,119 | |
|
| |
| |
| Total current assets | | 87,487,097 | | 88,430,778 | |
|
| |
| |
| Property and equipment, net | | 673,040 | | 813,794 | |
| Intangible assets, net | | 163,226,196 | | 165,985,767 | |
| Goodwill | | 27,478,307 | | 27,478,307 | |
| Deferred financing costs | | 4,334,577 | | 4,798,034 | |
| Restricted cash and investments | | 25,000,000 | | 25,000,000 | |
| Other assets | | 16,229 | | 16,229 | |
|
| |
| |
| Total assets | | $ 308,215,446 | | $ 312,522,909 | |
|
| |
| |
| | |
| | |
| | |
| | |
| Liabilities | |
| Current liabilities: | |
| Current maturities of long-term debt | | $ 13,920,058 | | $ 15,660,085 | |
| Milestone payable - ELESTRIN™ | | 3,252,145 | | 10,115,083 | |
| Accounts payable | | 5,734,167 | | 4,948,754 | |
| Accrued expenses | | 38,332,936 | | 38,728,413 | |
| Income taxes payable | | 2,168,979 | | — | |
|
| |
| |
| Total current liabilities | | 63,408,285 | | 69,452,335 | |
|
| |
| |
| Long-term liabilities: | |
| Long-term debt, less current maturities | | 51,479,901 | | 53,400,000 | |
| Deferred tax liabilities | | 647,063 | | 2,054,145 | |
|
| |
| |
| Total long-term liabilities | | 52,126,964 | | 55,454,145 | |
| | |
| Stockholders’ Equity | |
| Preferred stock, $0.01 par value; shares authorized: 2,000,000; no shares | |
| issued | | — | | — | |
| Common stock, $0.01 par value; authorized: 26,400,000 shares; issued | |
| and outstanding: 17,320,475 shares at March 31, 2007 and 16,965,578 shares | |
| at December 31, 2006 | | 173,205 | | 169,656 | |
| Class B common stock, $0.01 par value; authorized: 900,000 shares; issued and | |
| outstanding: 429,752 shares at March 31, 2007 and at December 31, 2006 | | 4,298 | | 4,298 | |
| Additional paid-in capital | | 145,791,723 | | 139,754,887 | |
| Retained earnings | | 50,002,067 | | 50,977,625 | |
| Accumulated other comprehensive loss | | 84 | | 1,143 | |
| Treasury stock – common stock – at cost; 877,058 shares at March 31, 2007 | |
| and December 31, 2006 | | (3,291,180 | ) | (3,291,180 | ) |
|
| |
| |
| Total stockholders’ equity | | 192,680,197 | | 187,616,429 | |
|
| |
| |
| Total liabilities and stockholders’ equity | | $ 308,215,446 | | $ 312,522,909 | |
|
| |
| |
| (a) | | Derived from audited financial statements. |
